Abstract |
TFC-612 inhibited thrombus formation on wire coils inserted into the lumen of the inferior vena cava of rats after 5 oral doses of 1.0 and 3.2 mg/kg and subcutaneous doses of 1.0 and 3.2 micrograms/rat/hr. This compound showed slight inhibition of platelet aggregation induced by collagen at 1.0 and 3.2 mg/kg (po) and significant inhibition at 10 mg/kg. TFC-612 had no effect on the plasma coagulation system at 3.2 mg/kg. Conversely, oral doses of 0.32-3.2 mg/kg dose- dependently enhanced fibrinolytic activity as measured by euglobulin clot lysis time and lysis area on fibrin plates by euglobulin fraction. TFC-612 did not enhance fibrinolytic activity in vitro. These results suggest that the enhancement of fibrinolytic activity by TFC-612, which may be due to an increase in tissue plasminogen activator release or reduction of plasminogen activator inhibitors release, contributes to its inhibition of thrombus formation.
|
Authors | Y Motoyama, Y Sakata, J Seki, M Sato, Y Namikawa, H Horiai, T Ono |
Journal | Thrombosis research
(Thromb Res)
Vol. 65
Issue 1
Pg. 55-63
(Jan 01 1992)
ISSN: 0049-3848 [Print] United States |
PMID | 1604443
(Publication Type: Journal Article)
|
Chemical References |
- Fibrinolytic Agents
- Platelet Aggregation Inhibitors
- TFC 612
- Alprostadil
|
Topics |
- Alprostadil
(analogs & derivatives, pharmacology)
- Animals
- Blood Coagulation
(drug effects)
- Disease Models, Animal
- Fibrinolytic Agents
(pharmacology)
- Male
- Platelet Aggregation Inhibitors
(pharmacology)
- Rats
- Rats, Inbred Strains
- Thrombophlebitis
(drug therapy)
|